よむ、つかう、まなぶ。
Global Health Vision of Ministry of Health, Labour and Welfare of Japan (13 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_42939.html |
| 出典情報 | 「厚生労働省国際保健ビジョン」の公表について（8／26）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
Japan has the potential to create the groundbreaking new drugs if it can strengthen
its research and development capabilities for drug discovery seeds from a global
ecosystem perspective and become a cornerstone of global drug discovery. This
would require building effective relationships of cooperation and coordination among
these stakeholders.
To strengthen drug discovery capabilities, it is important to build an ecosystem that
supports the establishment and growth of startup companies through mutual
cooperation among entrepreneurs, academia, government, and investors.
From this perspective, by attracting human resources and funding to Japan through
international collaboration, we aim to revitalize the drug discovery ecosystem by
facilitating the transition from research to development and reconstruct the foundation
of drug discovery in Japan.
② Contents
The MHLW will take the lead in introducing a new industrial policy to strengthen the
drug discovery infrastructure through public-private collaboration. The policy aims to
participate in the international drug discovery ecosystem and leverage human and
capital resources in Japan and abroad. The four main points are as follows.
i. With the aim of becoming a part of the international drug discovery ecosystem, we
will take a global approach and collaborate with top-notch human resources,
facilities, and companies across the world.
ii. To enhance Japan’s attractiveness as a base, we will establish a center equipped
with laboratory and hospital functions, where specialists can interact.
iii. To bridge the gap between basic research and clinical trials, we will secure human
resources and equipment to support the initial drug discovery process, train
biotechnicians, and develop facilities for GMP1 manufacturing.
iv. We will provide grants for basic research and development closely linked to drug
discovery from the outset, while collaborating with both the public and private
sectors.
③ Timeline
We will implement various measures based on the "Strategic Goal and Action Plan
for Improving Drug Discovery Capabilities to Support Early Availability of Innovative
1
Abbreviation for Good Manufacturing Practice
13
its research and development capabilities for drug discovery seeds from a global
ecosystem perspective and become a cornerstone of global drug discovery. This
would require building effective relationships of cooperation and coordination among
these stakeholders.
To strengthen drug discovery capabilities, it is important to build an ecosystem that
supports the establishment and growth of startup companies through mutual
cooperation among entrepreneurs, academia, government, and investors.
From this perspective, by attracting human resources and funding to Japan through
international collaboration, we aim to revitalize the drug discovery ecosystem by
facilitating the transition from research to development and reconstruct the foundation
of drug discovery in Japan.
② Contents
The MHLW will take the lead in introducing a new industrial policy to strengthen the
drug discovery infrastructure through public-private collaboration. The policy aims to
participate in the international drug discovery ecosystem and leverage human and
capital resources in Japan and abroad. The four main points are as follows.
i. With the aim of becoming a part of the international drug discovery ecosystem, we
will take a global approach and collaborate with top-notch human resources,
facilities, and companies across the world.
ii. To enhance Japan’s attractiveness as a base, we will establish a center equipped
with laboratory and hospital functions, where specialists can interact.
iii. To bridge the gap between basic research and clinical trials, we will secure human
resources and equipment to support the initial drug discovery process, train
biotechnicians, and develop facilities for GMP1 manufacturing.
iv. We will provide grants for basic research and development closely linked to drug
discovery from the outset, while collaborating with both the public and private
sectors.
③ Timeline
We will implement various measures based on the "Strategic Goal and Action Plan
for Improving Drug Discovery Capabilities to Support Early Availability of Innovative
1
Abbreviation for Good Manufacturing Practice
13